Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 17/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486860 | 0.82 | KDM4E (0.58) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL759745 | 0.82 | KDM4E (0.58) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL203020 | 0.82 | KDM4E (0.58) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL2756169 | 0.82 | KDM4E (0.58) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL91386 | 0.82 | KDM4E (0.62) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL12923050 | 0.79 | KDM4E (0.59) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL17232429 | 0.78 | RAB9A (0.65) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL17809500 | 0.78 | KDM4E (0.55) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL12895701 | 0.78 | KDM4E (0.55) | KDM4ERAB9ALMNAMAPTMEN1 | |
| SCHEMBL20322400 | 0.78 | KDM4E (0.66) | KDM4ERAB9ALMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101842357-A | Substituted pyrazole derivatives | TAKEDA PHARMACEUTICAL | 2010-09-22 | — | — | CN | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1270571-B1 | Heterocyclic compounds, their production and use | TAKEDA PHARMACEUTICAL (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1100762-B1 | ERYTHROMYCIN DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ZAMBON SPA (IT) | 2004-03-10 | — | — | EP | disclosed |
| EP-1270571-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6468979-B1 | ERYTHROMYCIN DERIVATIVES WITH BIHETEROCYCLIC GROUP AS SUBSTITUENT AT END OF CHAIN HAVE PARTICULARLY BROAD SPECTRUM OF ACTIVITY AND LONG DURATION OF ACTION | ZAMBON GROUP S.P.A. (IT) | 2002-10-22 | — | — | US | disclosed |
| CN-1349990-A | Heterocyclic compound, its preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-05-22 | — | — | CN | disclosed |
| CN-1077107-C | Heterocyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-01-02 | — | — | CN | disclosed |
| EP-1100762-A2 | ERYTHROMYCIN DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2001-05-23 | — | — | EP | disclosed |
| US-6211215-B1 | AROMATIC HETEROCYCLIC COMPOUND WITH AZOLE COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| WO-2000006606-A2 | ERYTHROMYCIN DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2000-02-10 | — | — | WO | disclosed |
| CN-1223653-A | Heterocyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-21 | — | — | CN | disclosed |
| EP-0912562-A1 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998003505-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | KDM4E 1414/4885RAB9A 3991/4885LMNA 4608/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | KDM4E 1440/4885RAB9A 4009/4885LMNA 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.